Mr. Henry Dubina reports

TELESCOPE INNOVATIONS TO DELIVER FIRST SELF-DRIVING LAB FOR KOREA'S LARGEST BIOPHARMA MANUFACTURERS ASSOCIATION

The Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) has purchased one of Telescope Innovations Corp.'s self-driving lab (SDL) platforms to be installed at a brand-new R&D (research and development) facility in Seoul in a matter of weeks. This groundbreaking facility aims to provide critical infrastructure to enable accelerated development of pharmaceuticals.

A self-driving lab is an automated platform that uses robotics, inline analytics, and AI (artificial intelligence) or machine-learning to run and optimize experiments in a continuous closed-loop workflow. Because it can operate continuously and adapt each experiment in real time, an SDL can complete and refine hundreds of experimental cycles far faster and with greater consistency than manual laboratory work. SDLs can dramatically accelerate iterative R&D, offering the potential to remove years from traditional development timelines and shorten the path from discovery to market-ready products. Telescope is recognized globally as one of the most advanced developers of self-driving lab systems, with a uniquely integrated platform that enables true closed-loop, autonomous chemical experimentation.

Telescope SDL to be implemented at the first AI-driven training hub in Korea

KPBMA is the largest trade association of Korea's pharmaceutical and biotech industry, with 300 domestic and multinational member companies. Key elements of KPBMA's mission are to support R&D and foster innovation in pharmaceutical manufacturing. This year, KPBMA launched its first SDL initiative through its Convergence AI Institute for Drug Discovery (CAIID) to promote automation and AI-driven experimentation. Telescope's SDLs will form part of the training hub to demonstrate innovative infrastructure, provide education and upskill researchers to fully capitalize on this new R&D method. Telescope is installing the SDL over the next few weeks, beyond which Telescope and KPBMA are building a strategic partnership for SDL deployment and adoption in Korea's pharmaceutical sector.

"We anticipate that this self-driving lab will bring significant innovation to new drug development processes in Korea," commented Junhee Pyo, CAIID vice-chief. "We also look forward to active global collaboration to facilitate technological exchange in this rapidly advancing field."

"Delivering our first self-driving lab in South Korea will mark a major milestone for Telescope's intelligent automation technology and for globally shifting the way pharmaceutical R&D is done," said Jason Hein, Telescope chief technology officer. "We're excited to be working closely with KPBMA and CAIID under their SDL initiative, and look forward to leading the deployment and adoption of SDLs in Asia."

"Asia represents one of the fastest-growing markets for lab automation and the digital R&D transformation," said Henry Dubina, Telescope chief executive officer. "Partnering with KPBMA on Korea's first AI-driven SDL hub positions Telescope at the centre of this momentum. We see this as the foundation for broader regional adoption of SDLs across research institutes and biopharma companies seeking faster, data-driven development."

Broader commercial opportunity for SDLs

Self-driving labs represent a platform technology gaining strong momentum in pharmaceutical R&D, and importantly they also offer growing applicability across agriculture, minerals and natural resources, energy, and the chemical industries. Their autonomous, adaptive operation makes SDLs effective in remote or high-risk environments where conventional laboratory workflows are difficult to maintain.

About Telescope Innovations Corp.

Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The company builds and deploys new enabling technologies, including flexible robotic platforms and artificial intelligence software that improve experimental throughput, efficiency and data quality. The company aims is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

We seek Safe Harbor.